## Supplemental Document:





Figure S1: Decreased levels of miRs are detected in the plasma of PTLD+ pediatric transplant recipients with monomorphic or polymorphic lesions as compared to controls. Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma of PTLD+ patients with early lesions, monomorphic/polymorphic lesions and matched controls. miR-106a, controls vs monomorphic/polymorphic lesions, p = 0.047 by one-way ANOVA.



Figure S2: The expression of miRs 17, 19, 106a, 155 and 194 did not differ significantly between the recipients of heart, kidney, liver and visceral transplants within PTLD+ and control groups. Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma of recipients of heart, kidney, liver and visceral transplant.

## Figure S3:

Α.







В.



Figure S3: Longitudinal analysis of plasma miRNA expression. (A) Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma samples collected at multiple timepoints post-transplant from PTLD+ patients (n = 8). (B) Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma samples collected post-transplant from control patients at timepoints matched with paired PTLD+ patients (n = 8).





Figure S4: Decreased levels of miRs are detected in the EV of PTLD+ pediatric transplant recipients with monomorphic polymorphic lesions compared or as to controls. Concentrations of miR-17, miR-19, miR-106a, miR-155 and miR-194 were measured by qPCR in plasma of PTLD+ patients with early lesions, monomorphic/polymorphic lesions and matched controls. miR-17, controls vs monomorphic/polymorphic lesions, p = 0.039; miR-19, controls vs monomorphic/polymorphic lesions, p = 0.044; miR-106a, controls VS monomorphic/polymorphic lesions, p = 0.009, by one-way ANOVA.